Wissenschaftliche Arbeiten

Uzm. Dr. Taliha Güçlü Kantar

33 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16868-5 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Prognostic Value of Systemic Inflammatory Markers in Locally Advanced or Metastatic Melanoma: A Real-World Analysis

    Cancers, 2026

    DOI 10.3390/cancers18030420 PMID 41681891 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  3. Differential Metastatic Patterns and Prognostic Value of Systemic Inflammation Scores in Anaplastic Lymphoma Kinase Rearranged Versus Anaplastic Lymphoma Kinase Negative Non-Small Cell Lung Cancer

    Cancers, 2026

    DOI 10.3390/cancers18030501 PMID 41681973 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  4. Meme Kanseri

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852 Frei zugänglicher VolltextQuelle: OpenAlex

  5. Role of Prognostic Nutritional Index and C-Reactive Protein/Albumin Ratio in Prognosis of Locally Advanced Nasopharyngeal Carcinoma

    Medicina, 2026

    DOI 10.3390/medicina62020377 PMID 41752776 Frei zugänglicher VolltextQuelle: OpenAlex

  6. Inflammation-tumor burden interaction score stratifies survival after irinotecan-eluting bead chemoembolization for colorectal liver metastases

    Frontiers in Medicine, 2026

    DOI 10.3389/fmed.2026.1751660 PMID 41907246 Frei zugänglicher VolltextQuelle: OpenAlex

  7. Prevalence and Prognostic Significance of Positron Emission Tomography–Computed Tomography–Defined Low Skeletal Muscle Mass (Radiological Sarcopenia) in Metastatic Breast Cancer

    Cerrahpaşa Medical Journal, 2026

    DOI 10.5152/cjm.2026.26112 Frei zugänglicher VolltextQuelle: ORCID

  8. Skeletal Muscle Index and Baseline Biomarkers in Atezolizumab-Treated Extensive-Stage Small-Cell Lung Cancer: A Real-World Cohort Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33100639 PMID 42930206 Frei zugänglicher VolltextQuelle: ORCID

  9. Prognostic Role of Inflammatory Indices and Real-World Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine

    Diagnostics, 2026

    DOI 10.3390/diagnostics16111746 PMID 42279613 Frei zugänglicher VolltextQuelle: ORCID

  10. The Royal Marsden Hospital Score Independently Predicts Overall Survival in Patients with De Novo Metastatic Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitors: A Multicenter Retrospective Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15103613 PMID 42194578 Frei zugänglicher VolltextQuelle: ORCID

  11. Association of Increased Cardio-Ankle Vascular Index (CAVI) with Echocardiographically Impaired Diastolic Dysfunction and Low Klotho Levels in Kidney Transplant Patients

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15072727 PMID 41977028 Frei zugänglicher VolltextQuelle: ORCID

  12. On-treatment dNLR and metastatic burden predict survival in advanced non-small-cell lung cancer treated with nivolumab

    Turkish Journal of Clinics and Laboratory, 2026

    DOI 10.18663/tjcl.1849630 Frei zugänglicher VolltextQuelle: ORCID

  13. Second Primary Malignancies After Appendiceal Neuroendocrine Tumors: A Contemporary SEER-Based Standardized Incidence Ratio Analysis (2015-2023)

    Asian Pacific journal of cancer prevention : APJCP, 2026

    DOI 10.31557/apjcp.2026.27.10.3857 PMID 42935079 Quelle: Europe PMC

  14. Integration of Ki67 and Pan-Immune-Inflammation Value (PIV) into a predictive nomogram for pathologic complete response in triple-negative breast cancer

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15842-5 PMID 41814226 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  15. Temporal Trends in Clinicopathological Features and Outcomes of De Novo Metastatic Luminal A Breast Cancer: A Retrospective Multicenter Analysis (2017–2025)

    Cancer Investigation, 2026

    DOI 10.1080/07357907.2025.2611945 PMID 41527482 Quelle: OpenAlex

  16. Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis

    Oncology Research and Treatment, 2026

    DOI 10.1159/000550484 PMID 41528926 Quelle: OpenAlex

  17. Temporal Trends in Clinicopathological Features and Outcomes of De Novo Metastatic Luminal A Breast Cancer: A Retrospective Multicenter Analysis (2017–2025)

    Figshare, 2026

    DOI 10.6084/m9.figshare.31055498 Frei zugänglicher VolltextQuelle: OpenAlex

  18. Meme Kanseri Epidemiyolojisi ve Risk Sınıflaması

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852.c2749 Quelle: OpenAlex

  19. Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15134880 PMID 42452343 Frei zugänglicher VolltextQuelle: OpenAlex

  20. Development of a Composite Risk Score and Real-world Outcomes in Advanced Pancreatic Adenocarcinoma: Prognostic Value of Baseline 18F-FDG PET/CT Metabolic Parameters

    Acta haematologica oncologica Turcica., 2026

    DOI 10.4274/ahot.galenos.2026.2026-7-3 Frei zugänglicher VolltextQuelle: OpenAlex

  21. Clinical Predictors of Progression-free Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Lu-177 PSMA: A Real-world Study

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-7-11 Frei zugänglicher VolltextQuelle: OpenAlex

  22. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 Zitationen (Europe PMC) Quelle: OpenAlex

  23. Prognostic Value of a New Marker, IBI Score and NLR Change in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (Prognostic value of IBI score and NLR change in NSCLC)

    Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi, 2025

    DOI 10.47572/muskutd.1603917 Frei zugänglicher VolltextQuelle: OpenAlex

  24. The impact of SARS-CoV-2 infection on the survival in NSCLC patients undergoing immunotherapy

    Pamukkale Medical Journal, 2025

    DOI 10.31362/patd.1598359 Frei zugänglicher VolltextQuelle: OpenAlex

  25. Real-World Outcomes of Treatment Approaches and the Impact of Systemic Inflammation Markers on Survival in Patients with Locally Advanced and Metastatic Laryngeal Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14248924 PMID 41464825 Frei zugänglicher VolltextQuelle: OpenAlex

  26. Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations

    Medicina, 2025

    DOI 10.3390/medicina61071160 PMID 40731790 7 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  27. Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer

    Medicina, 2025

    DOI 10.3390/medicina61111966 PMID 41303803 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  28. Medical oncologists’ dance with international guidelines and national reimbursement: insights from a survey in Türkiye

    Expert Review of Pharmacoeconomics & Outcomes Research, 2025

    DOI 10.1080/14737167.2025.2462238 PMID 39899025 Quelle: OpenAlex

  29. 3005P Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with sorafenib monotherapy: Real-world treatment patterns and clinical outcomes in Türkiye

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3619 Frei zugänglicher VolltextQuelle: OpenAlex

  30. Prognostic Value of ALBI Score and Lymphocyte-Associated Inflammation Markers in Advanced Hepatocellular Carcinoma: A Single Centre Retrospective Cross-Sectional Study

    Namık Kemal Tıp Dergisi, 2024

    DOI 10.4274/nkmj.galenos.2024.93898 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  31. Use of albumin and CRP related immuno-nutritional markers for prediction of locoregional response to treatment in unresectable hepatocellular carcinoma

    Pamukkale Medical Journal, 2024

    DOI 10.31362/patd.1471860 Frei zugänglicher VolltextQuelle: OpenAlex

  32. THE EFFECT OF PRE-TREATMENT INFLAMMATORY RESPONSE MARKERS ON SURVIVAL IN LOCALLY ADVANCED UNRESECTABLE AND METASTATIC GASTRIC CANCER: A RETROSPECTIVE CROSS-SECTIONAL STUDY

    Pamukkale Medical Journal, 2023

    DOI 10.31362/patd.1265291 Frei zugänglicher VolltextQuelle: OpenAlex

  33. PROGNOSTIC SIGNIFICANCE OF SYSTEMIC IMMUNE INFLAMMATION INDICES AND PROGNOSTIC NUTRITIONAL INDEX BEFORE CDK4/6 INHIBITOR THERAPY IN HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE METASTATIC BREAST CANCER PATIENTS

    Pamukkale Medical Journal, 2023

    DOI 10.31362/patd.1268419 Frei zugänglicher VolltextQuelle: OpenAlex